CDHs 3Q performance was unimpressive, with EBITDA margin declining ~750bps YoY to 17.1% and earnings de-growing ~35% YoY to Rs 2.8bn. This was largely on account of steep price erosion in the US base business. The top line was relatively better (~-2% YoY), supported by the sales of recently launched Asacol AG.